[ad_1]
Spencer Platt / Getty Images
- Needham, a Wall Street investment bank, asked each of its badysts which company, in their opinion, will outperform the market as a whole in the medium term.
- The Needham Conviction listing includes companies from a wide range of industries, including semiconductors, software, retail, and pharmaceuticals.
- Here are the 19 companies identified by Needham badysts as likely to outperform over the next year.
- Visit the Markets Insider homepage for more stories.
Needham has just published its very first Conviction List, a group of companies formed by badysts of the company. It is full of stock picks that, according to experts, will outperform the entire market over the next six months.
The selection of companies covers a wide range of industries, including software, semiconductors, pharmaceuticals and technologies.
"We expect these stocks to outperform the broad average total market return as well as other securities in the badyst universe over the next 12 months." the report says.
Markets Insider is looking for a millennial investor panel. If you are active in the markets, CLICK HERE to register.
Here are the 19 companies that, according to the Needham badyst, will outperform the overall market. They are listed in alphabetical order.
Apple
MASON TRINCA / Reuters
Ticker: APPL
Evaluation: Strong purchase
Price target: $ 225
Why: "We believe that Apple is moving from a hardware-based sales company to a society based on the growth in the number of subscribers and services. Laura Martin, an badyst at Needham, said, "The AAPL pivot to maximize its value over lifetime per single user suggests more steady revenue growth. , expanding margins and an expanding valuation multiples ".
Source: Needham & Company
Avalara
Insider Markets
Ticker: AVLR
Evaluation: Buy
Price target: $ 85
Why: Scott Bert, an badyst at Needham, said Avalara, which provides tax compliance software, will benefit from unholy clear winds and new partnership opportunities with e-commerce markets.
Source: Needham & Company
Boston Scientific
AP
Ticker: BSX
Evaluation: Strong purchase
Price target: $ 46
Why: "We believe that BSX has a solid product cycle that should enable it to outperform its competitors," said Mike Matson, an badyst at Needham.
Source: Needham & Company
Collegium Pharmaceutical
Insider Markets
Ticker: COLL
Evaluation: Buy
Price target: $ 33
Why: Collegium is currently trading an attractive valuation for investors, and the success of the company's Xtampza drug could help it achieve profitability by the end of the year, said badyst Serge Belanger. Needham.
Source: Needham & Company
Coupa Software
Insider Markets
Teleprinter: STROKE
Evaluation: Buy
Price target: $ 140
Why: Ryan MacDonald, an badyst at Needham, chose Coupa Software, specializing in enterprise expense management software, because he thought the company could grow by more than 30% in the next few years.
Source: Needham & Company
Cubic
Insider Markets
Teleprinter:LION CUB
Evaluation: Buy
Price target: $ 77
Why: "The CUB continues to add significant new contracts in its three operating segments, providing additional visibility on its near record multi-billion dollar backlog. "Said Jim Ricchiuti, an badyst at Needham.
Source: Needham & Company
Designer Brands
Glbad door
Ticker: DBI
Evaluation: Buy
Price target: $ 32
Why: "We place Designer Brands on the Needham list of convictions, because we are convinced that its business should improve during the 2H19, after the formation of moguls at 1H19, as well as for an even better year 2020, "said Rick Patel, badyst at Needham.
Source: Needham & Company
G1 Therapeutics
Insider Markets
Ticker: GTHX
Evaluation: Buy
Price target: $ 74
Why: Chad Messer, an badyst at Needham, said Trilaciclib of G1 Therapeutics, a drug for myeloconservation, is more likely to be approved by regulatory authorities.
Source: Needham & Company
Luckin Coffee
REUTERS / Jason Lee
Ticker: LK
Evaluation: Buy
Price target: $ 27
Why: "We believe in LK's profitability outlook, as the cost per item is expected to decrease significantly due to economies of scale and reduced promotions." Vincent Shenghao Yu, a Needham badyst, said.
Source: Needham & Company
Lumentum Holdings
Insider Markets
Teleprinter: LITE
Evaluation: Strong purchase
Price target: $ 62
Why: Lumentum, a telecommunications equipment manufacturer, has the dominant technology in the critical telecommunications markets, according to Alex Henderson, an badyst at Needham.
Source: Needham & Company
Marvell Technology Group
Insider Markets
Ticker: MRVL
Evaluation: Buy
Price target: $ 28
Why: "We believe that MRVL represents one of the best semiconductor games in the global deployment of 5G wireless infrastructure equipment," said Needham badyst N. Quinn Bolton.
Source: Needham & Company
New relic
Insider Markets
Ticker: NEWR
Evaluation: Buy
Price target: $ 131
Why: "NEWR is a provider of a complete monitoring solution that enables organizations to instrument and ensure continuous operability of critical applications, which is becoming increasingly important as companies expose more of their organizational facets to digital surfaces, "said Jack Andrews, an badyst at Needham.'s said.
Source: Needham & Company
ON Semiconductor
iStock / Getty Images More
Teleprinter: SURE
Evaluation: Strong purchase
Price target: $ 27
Why: Rajvindra Gill, an badyst at Needham, said ON Semiconductor's initiatives in the area of 5G infrastructure and server power management looked promising.
Source: Needham & Company
Rhythm Pharmaceuticals
Insider Markets
Ticker: RYTM
Evaluation: Buy
Price target: $ 42
Why: Alan Carr, an badyst at Needham, said that Rhythm was developing a treatment for rare disorders of obesity that could be approved and launched by the fourth quarter of 2020.
Source: Needham and Company
Holdings of SS & C Technologies
Insider Markets
Teleprinter:SS & C
Evaluation: Strong purchase
Price target: $ 77
Why: "We place SS & C Technologies Holdings on Needham's belief list, convinced that this company will be able to combine strong organic growth with acquisition synergies resulting from the acquisitions of DST, Eze Software and Intralinks in 2018, in order to generate exceptional growth in BPA. Needham badyst Mayank Tandon said in a research note.
Source: Needham & Company
TripAdvisor
Shutterstock
Teleprinter:TRIP
Evaluation: Buy
Price target: $ 63
Why: "We continue to believe that sponsored placements in the hotel industry, in particular, carry a potential downwind in the return to growth of the hotel, media and platform," said Brad Erickson, Analyst at Needham.
Source: Needham & Company
Veracyte
Insider Markets
Ticker: VCYT
Evaluation: Buy
Price target: $ 33
Why: Stephen Unger, an badyst at Needham, believes Veracyte could generate long-term revenue growth by marketing its expanding portfolio of diagnostic tests.
Source: Needham & Company
Vonage
Insider Markets
Ticker: VG
Evaluation: Buy
Price target: $ 14
Why: According to Richard Valera, an badyst at Needham, Vonage is well positioned to take advantage of the evolution of the telecommunications market towards an IP / cloud paradigm.
Source: Needham & Company
Zscaler
Insider Markets
Ticker: ZS
Evaluation: Strong purchase
Price target: $ 89
Why: "We believe that ZS is the first comprehensive cloud security platform based on the fundamentals needed to build a better security architecture, dramatically reduce the risk of breach, and ensure a consistent and scalable security policy, "said Alex. Henderson, badyst at Needham.
Source: Needham & Company
[ad_2]
Source link
